Attractiveness of France for International Clinical Trials in 2012: 6 thSurvey Assessed by Leem (French Association of Pharmaceutical Companies) état des lieux 2012 de l'attractivité de la France pour la recherche clinique internationale : 6e enquête du Leem

摘要

Since 2002, the Leem (French Association of Pharmaceutical Companies) has conducted a survey every two years to update the attractiveness of France for international clinical trials. Thirty companies (68 of the French market) have participated in this 6th survey which involved 79 countries, a greater number of Phases I/II, II and III studies (420 versus 352 in 2010), a relatively stable number ofincluded patients (246,895 versus 249,704 in 2010) and a greater number of centers (32,965 versus 24,337 in 2010). The evolution of time-lines for the go-ahead by French Authorities is heterogeneous (shortertime-lines by the French NationalAgency of Drug and Health Products Safety ANSM but longer time-lines by ResearchEthics Comittees CPP). The time-lines for first hospital contracts remain stable. France ranks at an average position amongEuropean countries in regards to quantitative and qualitative data, and its state-of-art in early stagesis still recognized. Its good performance in oncology and orphan diseases are major assets of competitiveness.